250602-53-0

Basic information

• Product Name: 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole
• Synonyms: 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole
• CAS NO: 250602-53-0
• Molecular Weight: 313.784
• Mol File: 250602-53-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole(250602-53-0)
• EPA Substance Registry System: 4-{[4-(chloromethyl)phenoxy]methyl}-5-methyl-2-phenyl-1,3-oxazole(250602-53-0)

Safety Data

• Hazardous Substances Data: 250602-53-0(Hazardous Substances Data)

Upstream product

• 250602-52-9 {4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]phenyl}methanol 
• 103789-66-8 4-(5-methyl-2-phenyl-4-oxazolylmethoxy)-benzaldehyde 

Downstream Products

• 1027443-74-8 2-[(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-hexanoic acid ethyl ester 
• 250601-83-3 methyl E-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutyrate 
• 1026273-16-4 5-[(E)-4-(5-Methyl-2-phenyl-oxazol-4-ylmethoxy)-benzyloxyimino]-5-phenyl-pentanoic acid ethyl ester 
• 250601-44-6 ethyl (E)-4-{4-[(5-methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino}-4-(4-phenoxyphenyl)butyrate 
• 250601-04-8 (E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutanoic acid 
• 250602-05-2 (E)-4-[4-(5-methyl-2-phenyl-4-oxazolylmethoxy)benzyloxyimino]-4-phenylbutylamide 
• 441355-04-0 methyl 2-[5-bromo-2-[4-[(5-methyl-2-phenyl-4-oxazolyl)methoxy]benzyloxy]phenyl]acetate 

Relevant articles and documents

BODY WEIGHT GAIN INHIBITORS

An agent for inhibiting body weight gain derived from a PPARγ agonist-like substance, which contains a PPARδ agonist-like substance, is useful for the treatment of diabetes and the like.

Studies on non-thiazolidinedione antidiabetic agents. 1. Discovery of novel oxyiminoacetic acid derivatives

A novel series of oxyiminoacetic acid derivatives were synthesized in an effort to develop a potent antidiabetic agent, which does not contain the 2,4-thiazolidinedione moiety. These compounds were evaluated for glucose and lipid lowering effects in genetically obese and diabetic KKAy mice. Several of the compounds showed strong antidiabetic activity, including functional potency at peroxisome proliferator-activated receptor (PPAR)-γ. (Z)-2-[4-[(5-Methyl-2-phenyl-1,3-oxazol-4-yl)methoxy]benzyloxyimino]-2-(4- phenoxyphenyl)acetic acid (25) significantly reduced plasma glucose (33%, p0.01) and plasma triglycelide levels (43%, p0.01) even at a dosage of 0.001% in diet. Pharmacokinetic analyses of 25 are also reported.

Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity

This invention provides a novel oxyiminoalkanoic acid derivative which has excellent hypoglycemic and hypolipidemic actions and which is used for the treatment of diabetes mellitus, hyperlipemia, insulin insensitivity, insulin resistance and impaired glucose tolerance.